Alterity Therapeutics Stock
Alterity Therapeutics Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- David A. Stamler
- Employees
- 11
- Market cap
- $44 M
- IPO
- 29/09/2003
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials…
Alterity Therapeutics stock: price history
1D
-3.7%
1W
-16.0%
1M
-31.9%
6M
-41.4%
YTD
-14.9%
1Y
-45.8%
2Y
+109.6%
5Y
-80.0%
10Y
-91.8%
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~22% stronger price swings than usual
Ask the agents about Alterity Therapeutics
Analyst assessment of Alterity Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$8.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
4
BUY
4
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 30/01/2025
Alterity Therapeutics stock metrics
P/E
-2.81
P/B
1.58
EV/EBITDA
-1.08
RETURN ON EQUITY
-32.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.5%
FLOAT SHARES
11,612,616
AVG. DAILY VOLUME (30D)
24,035
Insider transactions (SEC)
Marks Peter Ashley
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Alterity Therapeutics stock
What does Alterity Therapeutics do?
Alterity Therapeutics Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is David A. Stamler, the company employs around 11 people.
The IPO was on 29/09/2003; the stock trades on NASDAQ under the ticker ATHE.
What do analysts say about Alterity Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 30/01/2025).
The average price target is US$8.00, ranging from US$2.00 to US$12.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Alterity Therapeutics report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly 22% stronger than usual.
Does Alterity Therapeutics pay a dividend?
No, Alterity Therapeutics currently does not pay a dividend.
Which stocks are comparable to Alterity Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Alterity Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Alterity Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.